Verastem/$VSTM

1D1W1MYTD1Y5YMAX

About Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Health
Primary listing
NASDAQ
Employees
102
Headquarters
Needham, United States
Website
www.verastem.com

Verastem Metrics

BasicAdvanced
$680M
-
-$2.28
0.29
-

What the Analysts think about Verastem

Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Analyst projections of the future price of Verastem stock.

Bulls say / Bears say

AVMAPKI FAKZYNJA CO-PACK is generating commercial revenue, with Q2 net product revenue of $25.1 million versus $2.1 million a year earlier; this gives Verastem an approved product and an emerging revenue base to support its pipeline. (Verastem Q2 2026 results)
Updated RAMP 201 data showed durable benefit for avutometinib plus defactinib across KRAS-mutant and KRAS-wild-type recurrent LGSOC patients, while the confirmatory Phase 3 RAMP 301 trial was fully enrolled by December 2025. (Verastem Q1 2026 Form 10-Q)
VS-7375 has expanded into three registration-directed Phase 2 trials covering pancreatic, lung and colorectal cancers, with the FDA granting Fast Track Designation in NSCLC and preliminary data indicating dose-dependent activity and a manageable safety profile. (Verastem Q2 2026 results)
AVMAPKI FAKZYNJA CO-PACK’s approval is accelerated and remains contingent on confirmatory evidence from the Phase 3 RAMP 301 trial, creating regulatory and execution risk ahead of the expected mid-2027 readout. (Verastem Q1 2026 results)
Verastem remains loss-making and cash-intensive: Q2 operating expenses were $72.8 million versus $40.1 million of revenue, while R&D expenses rose 67% year over year to $41.3 million. Management projects funding only into the second half of 2027, leaving potential financing risk if launches or trials underperform. (Verastem Q2 2026 results)
VS-7375 is still clinically unproven: the March data update covered only 23 monotherapy patients with a mean treatment duration of 1.6 months, and the registration-directed studies are open-label Phase 2 trials whose efficacy and durability remain to be validated. (Verastem Q1 2026 results)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

Verastem Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Verastem Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Verastem News

AllArticlesVideos

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Business Wire1 week ago

Verastem Oncology to Participate in Upcoming September Investor Conferences

Business Wire2 weeks ago

Verastem Q2 Earnings Call Highlights

MarketBeat1 month ago

Funds containing Verastem

Funds
Fund name
Fund size
$VSTM weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.